Full text is available at the source.
Abstract
Evidence on the combined effectiveness and safety of GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes remains limited.
- GLP-1 receptor agonists and SGLT2 inhibitors are recognized as effective treatments for type 2 diabetes mellitus.
- Real-world studies assessing the combined use of these therapies are not well-established.
- The effectiveness and safety of GLP-1RA/SGLT2-i therapy is compared to standard treatment approaches.
Simplified